(Q45051059)

8 December 2017

title

Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). (English)

1 reference

chronic lymphocytic leukemia

8 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Eastern Cooperative Oncology Group

inferred from title

author

12

object named as

Eastern Cooperative Oncology Group

1 reference

8 December 2017

2

E Paietta

1 reference

8 December 2017

1

P H Wiernik

1 reference

8 December 2017

O Goloubeva

3

1 reference

8 December 2017

S J Lee

4

1 reference

8 December 2017

D Makower

5

1 reference

8 December 2017

J M Bennett

6

1 reference

8 December 2017

J L Wade

7

1 reference

8 December 2017

C Ghosh

8

1 reference

8 December 2017

L S Kaminer

9

1 reference

8 December 2017

J Pizzolo

10

1 reference

8 December 2017

M S Tallman

11

1 reference

8 December 2017

publication date

1 October 2004

1 reference

8 December 2017

1 reference

8 December 2017

volume

18

1 reference

8 December 2017

issue

10

1 reference

8 December 2017

page(s)

1605-1610

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403494

8 December 2017

exact match

0 references

cites work

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Theophylline in chronic asthma--evidence for disease-modifying properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Flow cytometry of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Mixed-Effects Models in Sand S-PLUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

Theophylline and the immune response: in vitro and in vivo effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Therapeutic efficacy of theophylline in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

The study of apoptotic cells by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403494

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403494

1 reference

Dimensions Publication ID

8 December 2017

1050706876

0 references

1 reference